Pfizer (NYSE:PFE) Stock Price Up 0.3% – Here’s Why

Pfizer Inc. (NYSE:PFE) traded up 0.3% on Thursday . The company traded as high as $26.07 and last traded at $25.78. 8,341,040 shares were traded during mid-day trading, a decline of 79% from the average session volume of 39,443,320 shares. The stock had previously closed at $25.71.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday. Finally, UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

The business’s fifty day simple moving average is $26.28 and its 200-day simple moving average is $27.18. The firm has a market cap of $145.11 billion, a P/E ratio of 18.17, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PFE. PKO Investment Management Joint Stock Co bought a new position in Pfizer in the fourth quarter worth $2,096,000. Northstar Financial Companies Inc. purchased a new position in Pfizer during the 4th quarter valued at about $854,000. Wealthedge Investment Advisors LLC bought a new stake in Pfizer during the fourth quarter worth about $207,000. Lighthouse Financial LLC bought a new stake in Pfizer during the fourth quarter worth about $301,000. Finally, Anchor Pointe Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $281,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.